An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?

Research output: Contribution to journalJournal articleResearchpeer-review

A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
Original languageEnglish
JournalNature Biotechnology
Issue number1
Pages (from-to)21-22
Number of pages2
Publication statusPublished - 3 Jan 2019


ID: 204531230